Corpus Interruptus: Biotech Drugs, Insurance Providers and the Treatment of Breast Cancer |
| |
| Authors: | Jane E. Schultz |
| |
| Affiliation: | (1) Department of English, Indiana University – Purdue University – Indianapolis, 425 University Blvd., Indianapolis, IN 46205, USA |
| |
| Abstract: | In researching the biomedically-engineered drug Neulasta (filgrastim), a breast cancer patient becomes aware of the extent to which knowledge about the development and marketing of drugs influences her decisions with regard to treatment. Time spent on understanding the commercial interests of insurers and pharmaceutical companies initially thwarts but ultimately aids the healing process. This first-person narrative calls for physicians to recognize that the alignment of commercial interests transgresses the patient’s humanity. |
| |
| Keywords: | Survivors Breast neoplasms Filgrastim Drug Industry Narration |
| 本文献已被 SpringerLink 等数据库收录！ |
|
